Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis

BACKGROUND: The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN pathway genes such as IFN regulatory factor 5 and 7 (IRF5 and IRF7), tyrosine kinase 2 (TYK2), signal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:RMD Open
Autors principals: Juge, Pierre-Antoine, Gazal, Steven, Constantin, Arnaud, Mariette, Xavier, Combe, Bernard, Tebib, Jacques, Dougados, Maxime, Sibilia, Jean, Le Loet, Xavier, Dieudé, Philippe
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2017
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5640092/
https://ncbi.nlm.nih.gov/pubmed/29071117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000448
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars